Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients

Aminoglycosides such as amikacin continue to be part of the backbone of treatment of multidrug-resistant tuberculosis (MDR-TB). We measured amikacin concentrations in 28 MDR-TB patients in Botswana receiving amikacin therapy together with oral levofloxacin, ethionamide, cycloserine, and pyrazinamide...

Descripción completa

Detalles Bibliográficos
Autores principales: Modongo, Chawangwa, Pasipanodya, Jotam G., Magazi, Beki T., Srivastava, Shashikant, Zetola, Nicola M., Williams, Scott M., Sirugo, Giorgio, Gumbo, Tawanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038293/
https://www.ncbi.nlm.nih.gov/pubmed/27458224
http://dx.doi.org/10.1128/AAC.00962-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038293/
https://www.ncbi.nlm.nih.gov/pubmed/27458224
http://dx.doi.org/10.1128/AAC.00962-16

Ejemplares similares